Home › Funds › EDGAR LOMAX CO/VA › GILD
EDGAR LOMAX CO/VA position in GILD
GILEAD SCIENCES INC · Health Care
EDGAR LOMAX CO/VA reported holding 146,040 shares of GILD (GILEAD SCIENCES INC) in its Q3 2026 13F filing — a position valued at US$21.8M, representing 1.65% of its reported portfolio and ranking #21 among its reported holdings. EDGAR LOMAX CO/VA has disclosed GILD holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How EDGAR LOMAX CO/VA's GILD position evolved
EDGAR LOMAX CO/VA first disclosed a stake in GILD in Q3 2023 at 103,924 shares (US$7.8M). The position peaked in Q1 2025 at 231,390 shares, worth US$25.9M. Across 13 filings, EDGAR LOMAX CO/VA increased the stake 2 time(s), trimmed it 10 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 146,040 shares valued at US$21.8M — a reduction of -1,600 shares quarter over quarter.. Notable position changes include a 32% increase in Q1 2024 (shares fell 6% over the following quarter), a 84% increase in Q1 2025 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 103.92K | $7.79M | New |
| Q4 2023 | 99.90K | $8.09M | Reduce |
| Q1 2024 | 132.31K | $9.69M | Add |
| Q2 2024 | 129.98K | $8.92M | Reduce |
| Q3 2024 | 127.99K | $10.73M | Reduce |
| Q4 2024 | 125.59K | $11.60M | Reduce |
| Q1 2025 | 231.39K | $25.93M | Add |
| Q2 2025 | 227.66K | $25.24M | Reduce |
| Q3 2025 | 175.30K | $19.46M | Reduce |
| Q4 2025 | 171.33K | $21.03M | Reduce |
| Q1 2026 | 156.71K | $21.84M | Reduce |
| Q2 2026 | 147.64K | $18.65M | Reduce |
| Q3 2026 | 146.04K | $21.77M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GILD and 13F data
GILD (GILEAD SCIENCES INC) is a Health Care company. 34 other funds we track also report a position in GILD — the largest reported positions include Fidelity Management & Research (FMR) (US$8.68B), Invesco Ltd (US$5.76B), Capital World Investors (US$5.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GILD
- Fidelity Management & Research (FMR) 58.27M sh · $8.68B · Q3 2026
- Invesco Ltd 38.66M sh · $5.76B · Q3 2026
- Capital World Investors 35.93M sh · $5.36B · Q3 2026
- Capital World Investors 40.99M sh · $5.18B · Q2 2026
- PRICE T ROWE ASSOCIATES INC /MD/ 30.00M sh · $3.79B · Q2 2026
- Capital Research Global Investors 23.98M sh · $3.57B · Q3 2026
- Dodge & Cox 23.68M sh · $2.99B · Q2 2026
- DODGE & COX 23.68M sh · $2.99B · Q2 2026
- MFS Investment Management 11.46M sh · $1.77B · Q3 2026
- Amundi US 11.26M sh · $1.68B · Q3 2026
- Deutsche Bank AG 9.61M sh · $1.43B · Q3 2026
- Boston Partners 6.52M sh · $970.37M · Q3 2026
More on EDGAR LOMAX CO/VA
FAQ
How long has EDGAR LOMAX CO/VA held GILD?
EDGAR LOMAX CO/VA has disclosed GILD holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is EDGAR LOMAX CO/VA's current position in GILD?
As of Q3 2026, EDGAR LOMAX CO/VA holds 146.04K shares of GILD (GILEAD SCIENCES INC), valued at $21.77M, representing 1.65% of its reported portfolio and ranking #21.
Has EDGAR LOMAX CO/VA been buying or selling GILD?
In the latest 13F filing (Q3 2026), EDGAR LOMAX CO/VA reduced its position in GILD. The position peaked in Q1 2025 at 231.39K shares.
Which other funds hold GILD?
Other major institutional holders of GILD include Fidelity Management & Research (FMR), Invesco Ltd, Capital World Investors, among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.